| Keywords: |
cancer chemotherapy; treatment outcome; disease-free survival; cancer surgery; surgical technique; survival rate; review; fluorouracil; diarrhea; multimodality cancer therapy; treatment planning; capecitabine; cancer adjuvant therapy; cancer radiotherapy; postoperative care; preoperative care; radiation dose; chemotherapy, adjuvant; combined modality therapy; radiotherapy, adjuvant; cancer staging; neoplasm staging; adenocarcinoma; ki 67 antigen; bolus injection; leukopenia; vincristine; continuous infusion; tumor marker; prediction; lomustine; radiation dosage; irinotecan; postoperative complications; folinic acid; adjuvant chemotherapy; cycline; oxaliplatin; thymidylate synthase inhibitor; rectum carcinoma; rectal neoplasms; intestine function; adjuvant radiotherapy; leucovorin; drug administration routes; intravenous drug administration; small intestine obstruction; biological tumor markers; raltitrexed; 5 chloro 2,4 dihydroxypyridine plus oxonate potassium plus tegafur; levamisole; uft; trimetrexate; edrecolomab; semustine; anus; humans; human; priority journal; 5 ethynyluracil; combined antineoplastic agents; high- energy radiotherapy; mesentery/surgery
|
